DOCSLIB.ORG

Preferred Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Preferred Drug List QL dicloxacillin methenamine BETA BLOCKERS and QL fenofibrate QL penicillin VK QL mefloquine COMBINATIONS QL gemfibrozil SULFONAMIDES metronidazole tabs acebutolol QL lovastatin sulfamethoxazole neomycin atenolol QL OTC niacin IR, ER Preferred Drug List /trimethoprim QL nitrofurantoin caps atenolol/chlorthalidone QL pravastatin KEY: TETRACYCLINES praziquantel betaxolol QL simvastatin * age restrictions apply doxycycline monohydrate pyrazinamide bisoprolol, bisoprolol/HCTZ PCSK-9 INHIBITORS PA requires prior (capsules/suspension only) rifabutin carvedilol PA evolocumab authorization minocycline IR rifampin caps labetalol MISCELLANEOUS AGENTS ST requires trial of first step tetracycline rifapentine metoprolol digoxin tab/soln product ANTIFUNGALS rifater QL metoprolol HCTZ QL daily dosage limits apply QL clotrimazole troches metoprolol ext rel CENTRAL NERVOUS SYSTEM RX legend prescription QL fluconazole CARDIOVASCULAR AGENTS nadolol ALZHEIMER’S DISEASE product QL griseofulvin ACE INHIBITORS and propranolol, QL donepezil OTC over-the-counter available by QL griseofulvin microsize oral COMBINATIONS propranolol ext rel QL galantamine prescription suspension QL benazepril, benazepril/HCTZ sotalol QL galantamine ER QL ketoconazole cream, shampoo captopril, captopril/HCTZ CALCIUM CHANNEL BLOCKERS ANALGESICS ANTIBACTERIALS QL nystatin enalapril, enalapril/HCTZ QL amlodipine QL* codeine/APAP ANTIBIOTICS QL OTC terbinafine QL fosinopril, fosinopril/HCTZ QL diltiazem ext-rel QL PA fentanyl citrate lozenge CEPHALOSPORINS ANTIVIRALS — HEPATITIS C QL lisinopril, lisinopril/HCTZ QL felodipine ext-rel QL PA fentanyl transdermal First Generation PA QL elbasiv/grazoprevir moexipril, moexipril/HCTZ QL isradipine QL hydrocodone/acetaminophen QL cefadroxil (Zepatier) quinapril, quinapril/HCTZ QL nifedipine ext-rel QL hydromorphone QL cephalexin PA glecaprevir/pibrentasvir ANGIOTENSIN II RECEPTOR QL nicardipine QL meperidine Second Generation (Mavyret) BLOCKERS QL verapamil ext-rel QL PA methadone QL cefaclor PA peginterferon alfa 2a QL candesartan, DIURETICS QL morphine tab, soln, suppository QL cefprozil PA peginterferon alfa 2b candesartan/HCTZ amiloride QL morphine ER tab QL cefuroxime axetil ribavirin QL irbesartan, irbesartan/HCTZ amiloride/HCTZ QL oxycodone, oxycodone/APAP Third Generation PA QL sofosbuvir (Sovaldi) QL losartan, losartan/HCTZ bumetanide HYLAURONICS QL cefdinir ANTIVIRALS QL valsartan, valsartan/HCTZ chlorthalidone PA hyaluronate sodium (Euflexxa) QL cefpodoxime acyclovir ANTICOAGULANTS furosemide PA hyaluronate sodium (Gelsyn) FLUOROQUINOLONES QL famciclovir apixaban hydrochlorothiazide PA hyaluronate sodium (Supartz QL* ciprofloxacin tabs QL valacyclovir PA QL enoxaparin indapamide FX) * ofloxacin HIV/AIDS jantoven metolazone MISCELLANEOUS MACROLIDES Please see Amerigroup formulary for QL rivaroxaban spironolactone QL lidocaine crm/HC covered agents. QL azithromycin warfarin spironolactone/HCTZ lidocaine jelly, gel MISCELLANEOUS QL clarithromycin ANTIPLATELET AGENTS (25/25mg only) QL lidocaine sol albendazole QL erythromycin (all salt forms) QL OTC aspirin torsemide lidocaine/pramoxine crm atovaquone-proquanil PENICILLINS cilostazol triamterene/HCTZ (without applicator) clindamycin QL amoxicillin QL clopidogrel LIPID LOWERING AGENTS QL PA lidocaine topical patch ethambutol QL amoxicillin/clavulanate QL dipyridamole QL cholestyramine QL tramadol; tramadol/APAP isoniazid QL ampicillin colestipol ivermectin Version Date: 2/1/2018 WEBMGA-0242-17 Applies to Medicaid market- Georgia QL trimipramine QL buspirone bromocriptine 1.2- 5% gel ANTICONVULSANTS SNRIs QL chlordiazepoxide carbidopa/levodopa OTC Differin 0.1% gel QL carbamazepine QL venlafaxine QL clonazepam carbidopa/levodopa XR erythromycin 2% pad, soln QL clonazepam tabs QL venlafaxine XR QL clorazepate QL carbidopa/entacapone metronidazole 0.75% cream, lotion, QL diazepam rectal gel SSRIs QL diazepam /levodopa gel QL divalproex DR, ER, QL citalopram QL hydroxyzine hcl, pamoate pramipexole metronidazole 1% gel, gel pump sprinkle QL escitalopram QL lorazepam ropinirole rosadan 0.75% cream, gel QL epitol QL fluoxetine (except 60mg) QL oxazepam selegiline caps, tabs * tretinoin gel (0.01%, 0.025%) QL ethosuximide QL fluvoxamine ATTENTION DEFICIT HYPERACTIVITY trihexyphenidyl * tretinoin gel micro 0.1% tube QL felbamate QL paroxetine hcl DISORDER SEDATIVE/HYPNOTICS * tretinoin cream (0.025%, QL gabapentin QL sertraline QL* amphet/dextroamph, ER QL estazolam 0.05%, 0.1%) QL lamotrigine disper tab, ER, ANTIPSYCHOTICS — oral QL* atomoxetine QL temazepam (15/30mg only) * tretinoin emollient crm 0.05% ODT QL * aripiprazole (tabs only) QL* clonidine ER QL PA triazolam ANTIBACTERIALS QL levetiracetam QL * carbamazepine QL* dexmethylphenidate QL zolpidem OTC chlorhexidine QL oxcarbazepine QL * chlorpromazine QL* dexmethylphenidate ER QL zaleplon mupirocin oint QL phenobarbital QL * clozapine QL* dextroamphetamine, XR silver sulfadiazine QL phenytoin sod ext-rel QL * lithium carbonate QL* methylphenidate, XR COUGH & COLD CORTICOSTEROIDS QL phenytoin tabs, chewableQL QL * lithium carbonate ext rel MIGRAINE benzonatate Products are grouped based upon relative primidone QL* lithium solution QL amitriptyline QL OTC* dextromethorphan syrup potency. QL roweepra QL * loxapine QL butalbital/APAP QL OTC diphenhydramine liquid, LOW QL tiagabine (2mg and 4mg) QL * olanzapine tab QL butalbital/APAP/caff capsules QL RX/OTC hydrocortisone crm, QL topiramate QL * paliperidone ext rel QL* butalbital/APAP/caff/codeine QL OTC* guaifenesin syrup lot, oint QL valproic acid QL * perphenazine QL butalbital/ASA QL* guaifenesin w/codeine OTC QL hydrocortisone-aloe 1% cr QL zonisamide QL* pimozide QL butalbital/ASA/caff syrup MEDIUM ANTIDEPRESSANTS QL* risperidone tab/soln QL* butalbital/ASA/caff/codeine QL* promethazine w/codeine QL betamethasone valerate crm QL amitriptyline QL* quetiapine IR QL naratriptan syrup QL fluticasone propionate crm, QL amitrip/perphenazine QL* thioridazine propranolol, XR QL* promethazine w/DM oint QL amoxapine QL* thiothixene QL sumatriptan tabs syrup QL mometasone furoate crm, QL bupropion, IR, SR, XL QL* trifluoperazine QL ST sumatriptan inj, spray QL * pseudoehedrine syrup, oint, soln QL chlordiazepoxide QL* ziprasidone OPIOID/ALCOHOL DEPENDANCE tablets QL triamcinolone acet crm, /amitriptyline ANTIPSYCHOTICS — injectables QL acamprosate tab QL * saline spray, drops oint QL desipramine * PA aripiprazole (Abilify Maintena) QL buprenorphine DERMATOLOGY HIGH QL doxepin * PA aripiprazole lauroxil (Aristada PA QL buprenorphine/naloxone QL amcinonide oint, lot ACNE ORAL QL imipramine QL* fluphenazine decan, inj SL tabs/film QL betamethasone dipr aug crm PA claravis minocycline IR QL maprotiline QL* haloperidol inj. disulfiram QL betamethasone dipr lotion PA myorisan tetracycline QL mirtazapine *PA olanzapine (Zyprexa Relprevv) naloxone inj syr and vials QL betamethasone valerate oint PA zenatane QL nortriptyline *PA paliperidone(InvegaSustenna) QL naloxone nasal spray QL diflorasone diacetate crm ACNE TOPICAL QL phenelzine *PA paliperidone (Invega Trinza) naltrexone tab QL fluocinonide E cream PA adapalene cream, gel QL protriptyline *PA risperidone (Risperdal Consta) PARKINSON’S DISEASE QL triamcinolone acet crm, oint QL OTC benzoyl peroxide QL tranylcypromine ANXIETY QL amantadine (tablets only) VERY HIGH clindamycin 1% gel, pad, soln QL trazodone QL alprazolam benztropine QL clobetasol E propionate crm clindamycin-benzoyl peroxide Version Date: 2/1/2018 WEBMGA-0242-17 Applies to Medicaid market- Georgia QL clobetasol propionate crm, gel, ciprofloxacin 0.2% otic sol QL alcohol prep pads octreotide QL tizanidine (tablets only) oint, soln neomycin/polymyxin B/hc (various) tabloid NSAIDs QL halobetasol propionate crm, QL ofloxacin otic ORAL AGENTS trexall diclofenac oint ANTIHISTAMINES ST empagliflozin GASTROINTESTINAL etodolac FUNGAL INFECTIONS QL azelastine spray 0.1% ST empagliflozin/metformin DIARRHEA ibuprofen OTC butenafine HCL QL cyproheptadine glimepiride diphenoxylate/atropine indomethacin QL PA ciclodan 8% soln QL OTC diphenhydramine glipizide, glipizide ext-rel OTC QL loperamide (tabs only) ketorolac tromethamine QL PA ciclopirox 8% soln QL OTC* fexofenadine QL glyburide, glyburide EMESIS meloxicam OTC clotrimazole QL OTC loratadine micronized OTC meclizine nabumetone ketoconazole INTRANASAL STEROIDS QL glyburide/metformin metoclopramide naproxen sodium OTC miconazole nitrate QL OTC fluticasone ST linagliptin QL ondansetron ODT piroxicam nystatin QL OTC tiamcinolone ST linagliptin/metformin prochlorperazine sulindac OTC generic terbinafine HCL QL metformin, metformin XR promethazine MISC. ANTIRHEUMATIC cream ELECTROLYTIC AND RENAL AGENTS QL nateglinide GERD/HEARTBURN/ULCERS azathioprine terbinafine tab calcium acetate QL pioglitazone/glimeperide OTC QL esomeprazole leflunomide OTC tolnaftate PA sucroferric oxyhydroxide QL pioglitazone/metformin OTC RX famotidine oral/inj methotrexate SCABIES AND PEDICULOSIS (Velphoro) QL repaglinide OTC QL lansoprazole sulfasalazine QL permethrin 5% cream ST sitagliptin * nizatidine MISC. IMMUNOSUPRRESIVE QL OTC permethrin 1% rinse ENDOCRINOLOGY ST sitagliptin/metformin (XR) OTC QL omeprazole cyclosporine OTC pyrethrins/piperonyl HORMONE THERAPY gengraf ANTIDIABETICS OTC RX ranitidine (tabs, caps, butoxide 4% PA QL testosterone 1% gel mycophenolic acid INJECTABLE AGENTS syrup) spinosad 0.9% topical PA testosterone cyp inj sirolimus ST albiglutide INFLAMMATORY BOWEL DISEASE suspension PA testosterone enan inj tacrolimus QL ST liraglutide
Load more

Recommended publications
  • LGM-Pharma-Regulatory-1527671011
    Pipeline Products List Specialty Portfolio Updated Q2 2018 Updated Q2 2018 See below list of newly approved API’s, samples are readily available for your R&D requirements: Inhalation Ophthalmic Transdermal Sublingual Abaloparatide Defibrotide Sodium Liraglutide Rituximab Abciximab Deforolimus Lixisenatide Rivastigmine Aclidinium Bromide Azelastine HCl Agomelatine Alprazolam Abemaciclib Delafloxacin Lumacaftor Rivastigmine Hydrogen Tartrate Beclomethasone Dipropionate Azithromycin Amlodipine Aripiprazole Acalabrutinib Denosumab Matuzumab Rizatriptan Benzoate Budesonide Besifloxacin HCl Apomorphine Eletriptan HBr Aclidinium Bromide Desmopressin Acetate Meloxicam Rocuronium Bromide Adalimumab Difluprednate Memantine Hydrochloride Rolapitant Flunisolide Bimatoprost Clonidine Epinephrine Aflibercept Dinoprost Tromethamine Micafungin Romidepsin Fluticasone Furoate Brimonidine Tartrate Dextromethorphan Ergotamine Tartrate Agomelatine Dolasetron Mesylate Mitomycin C Romosozumab Fluticasone Propionate Bromfenac Sodium Diclofenac Levocetrizine DiHCl Albiglutide Donepezil Hydrochloride Mometasone Furoate Rotigotine Formoterol Fumarate Cyclosporine Donepezil Meclizine Alectinib Dorzolamide Hydrochloride Montelukast Sodium Rucaparib Iloprost Dexamethasone Valerate Estradiol Melatonin Alemtuzumab Doxercalciferol Moxifloxacin Hydrochloride Sacubitril Alirocumab Doxorubicin Hydrochloride Mycophenolate Mofetil Salmeterol Xinafoate Indacaterol Maleate Difluprednate Fingolimod Meloxicam Amphotericin B Dulaglutide Naldemedine Secukinumab Levalbuterol Dorzolamide
    [Show full text]
  • Nizatidine) Oral Solution
    Axid® (nizatidine) Oral Solution Description: Nizatidine (USP) is a histamine H2-receptor antagonist. Chemically, it is N-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1- ethenediamine. The structural formula is as follows: Nizatidine has the empirical formula C12H21N5O2S2 representing a molecular weight of 331.47. It is an off-white to buff crystalline solid that is soluble in water. Nizatidine has a bitter taste and mild sulfur-like odor. Axid® Oral Solution is formulated as a clear, yellow, oral solution with bubble gum flavor and each 1 mL contains 15 mg of nizatidine. Axid® Oral Solution also contains the inactive ingredients methylparaben, propylparaben, glycerin, sodium alginate, purified water, sodium chloride, saccharin sodium, sodium citrate dihydrate, citric acid anhydrous, sucrose, bubble gum flavor, artificial sweetness enhancer, and sodium hydroxide. Clinical Pharmacology in Adults: Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. Antisecretory Activity—1. Effects on Acid Secretion: Nizatidine significantly inhibited nocturnal gastric acid secretion for up to 12 hours. Nizatidine also significantly inhibited gastric acid secretion stimulated by food, caffeine, betazole, and pentagastrin (Table 1). Table 1. Effect of Oral Nizatidine on Gastric Acid Secretion % Inhibition of Gastric Acid Output by Dose (mg) Time After Dose (h) 20-50 75 100 150 300 Nocturnal Up to 10 57 - 73 - 90 Betazole Up to 3 - 93 - 100 99 Pentagon Up to 6 - 25 - 64 67 Meal Up to 4 41 64 - 98 97 Caffeine Up to 3 - 73 - 85 96 2. Effects on Other Gastrointestinal Secretions—Pepsin: Oral administration of 75 to 300 mg of nizatidine did not affect pepsin activity in gastric secretions.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Conceptual Model for Using Imidazoline Derivative Solutions in Pulpal Management
    Journal of Clinical Medicine Review Conceptual Model for Using Imidazoline Derivative Solutions in Pulpal Management Robert S. Jones Division of Pediatric Dentistry, Department of Developmental & Surgical Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA; [email protected] Abstract: Alpha-adrenergic agonists, such as the Imidazoline derivatives (ImDs) of oxymetazoline and xylometazoline, are highly effective hemostatic agents. ImDs have not been widely used in dentistry but their use in medicine, specifically in ophthalmology and otolaryngology, warrants consideration for pulpal hemostasis. This review presents dental healthcare professionals with an overview of ImDs in medicine. ImD solutions have the potential to be more effective and biocompatible than existing topical hemostatic compounds in pulpal management. Through a comprehensive analysis of the pharmacology of ImDs and the microphysiology of hemostasis regulation in oral tissues, a conceptual model of pulpal management by ImD solutions is presented. Keywords: hemostasis; alpha-adrenergic agonists; imidazoline; oxymetazoline; nasal; dental pulp; mucosa; apexogenesis; pulpotomy; direct pulp cap; dentistry 1. Overview Citation: Jones, R.S. Conceptual The purpose of this review is to formulate a conceptual model on the potential man- Model for Using Imidazoline agement of pulpal tissue by imidazoline derivatives (ImDs) based on a review of the Derivative Solutions in Pulpal literature that examines the hemostatic properties and mechanistic actions of these com- Management. J. Clin. Med. 2021, 10, 1212. https://doi.org/10.3390/ pounds in other human tissues. Commercial ImDs are formulated in solution with an- jcm10061212 timicrobial preservatives in order to act as ‘parenteral topical agents’ and used to manage ophthalmic inflammation, nasal congestion, and to control bleeding during otolaryngology Academic Editor: Rosalia surgery [1,2].
    [Show full text]
  • Transient Mydriasis Due to Opcon-A
    Open Access Austin Journal of Clinical Ophthalmology Special Article - Ophthalmology: Clinical Cases and Images Transient Mydriasis Due to Opcon-A Hava Donmez Keklikoglu1, Aubrey Gilbert2 and Nurhan Torun3* Abstract 1Department of Neurology, Ataturk Education and Opcon-A (pheniramine maleate/ naphazoline hydrochloride) is a topical Research Hospital, Turkey decongestant and antihistamine combination that is used to treat ocular allergies. 2Department of Ophthalmology, Massachusetts Eye and It is sold as an over the counter eye drop and is generally associated with very Ear Infirmary, USA few side effects. It may, however, cause mydriasis in some patients, though this 3Division of Ophthalmology, Department of Surgery, Beth is not a well-recognized occurrence. We present three cases in which transient Israel Deaconess Medical Center, USA mydriasis was attributed to Opcon-A use and emphasize consideration of this *Corresponding author: Nurhan Torun, Division drug in the differential diagnosis of temporary pupillary dilation. of Ophthalmology, Department of Surgery, Beth Israel Keywords: Transient mydriasis; Anisocoria; Naphazoline; Pheniramine; Deaconess Medical Center, 330 Brookline Avenue, Opcon-A Boston, MA 02215, USA Received: April 30, 2015; Accepted: May 04, 2015; Published: May 06, 2015 Case Reports the eye. Based on this history and his normal exam he was diagnosed with pharmacological mydriasis. He was advised not to use Opcon-A Case 1 and his pupillary dilation did not recur. A 29-year-old man was seen in Ophthalmology Clinic for a dilated left pupil which he had noted a few hours earlier on the day Case 3 of presentation. He had no other acute complaints. His past medical A 24-year-old woman was seen in Ophthalmology Clinic for history was notable for asthma for which he occasionally used an three separate episodes of transient right pupillary dilation lasting a inhaler.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Maintenance Drug List
    Commonly Prescribed Maintenance Medications Maintenance (or long-term) medications are those dosage form may be used to treat more than one drugs you may take on a regular basis to treat conditions medical condition. In these cases, each medication may such as high cholesterol, high blood pressure or diabetes. be classified according to its first U.S. Food and Drug Based on your benefit plan, you may get up to a 90-day Administration (FDA) approved use. Some strengths supply of covered maintenance medication delivered and/or formulations listed may not be covered. to you through a home delivery program or at select Please note that oral contraceptives are maintenance retail pharmacies. medications and are part of this list. However, this Some plans may require you to fill these prescriptions list does not include the trade names of all available through home delivery or at select retail pharmacies oral contraceptives because there are a large number in order to receive coverage. of products. Commonly used maintenance medications are listed in Coverage is always subject to the terms and limits of this guide. This list is not all-inclusive and may change your benefit plan. Please verify with your plan if there from time to time. are any additional requirements before a drug may be Most generic drugs listed are followed by a reference covered. For details about your plan, check your benefit brand drug in (parentheses). The brand name drug materials or call the number on your member ID card. in parentheses is listed for reference and may not be Third-party brand names are the property of their covered under your benefit.
    [Show full text]
  • Receptor Antagonist (H RA) Shortages | May 25, 2020 2 2 2 GERD4,5 • Take This Opportunity to Determine If Continued Treatment Is Necessary
    H2-receptor antagonist (H2RA) Shortages Background . 2 H2RA Alternatives . 2 Therapeutic Alternatives . 2 Adults . 2 GERD . 3 PUD . 3 Pediatrics . 3 GERD . 3 PUD . 4 Tables Table 1: Health Canada–Approved Indications of H2RAs . 2 Table 2: Oral Adult Doses of H2RAs and PPIs for GERD . 4 Table 3: Oral Adult Doses of H2RAs and PPIs for PUD . 5 Table 4: Oral Pediatric Doses of H2RAs and PPIs for GERD . 6 Table 5: Oral Pediatric Doses of H2RAs and PPIs for PUD . 7 References . 8 H2-receptor antagonist (H2RA) Shortages | May 25, 2020 1 H2-receptor antagonist (H2RA) Shortages BACKGROUND Health Canada recalls1 and manufacturer supply disruptions may be causing shortages of commonly used acid-reducing medications called histamine H2-receptor antagonists (H2RAs) . H2RAs include cimetidine, famotidine, nizatidine and ranitidine . 2 There are several Health Canada–approved indications of H2RAs (see Table 1); this document addresses the most common: gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) . 2 TABLE 1: HEALTH CANADA–APPROVED INDICATIONS OF H2RAs H -Receptor Antagonists (H RAs) Health Canada–Approved Indications 2 2 Cimetidine Famotidine Nizatidine Ranitidine Duodenal ulcer, treatment ü ü ü ü Duodenal ulcer, prophylaxis — ü ü ü Benign gastric ulcer, treatment ü ü ü ü Gastric ulcer, prophylaxis — — — ü GERD, treatment ü ü ü ü GERD, maintenance of remission — ü — — Gastric hypersecretion,* treatment ü ü — ü Self-medication of acid indigestion, treatment and prophylaxis — ü† — ü† Acid aspiration syndrome, prophylaxis — — — ü Hemorrhage from stress ulceration or recurrent bleeding, — — — ü prophylaxis ü = Health Canada–approved indication; GERD = gastroesophageal reflux disease *For example, Zollinger-Ellison syndrome .
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Lifitegrast for the Treatment of Dry Eye Disease in Adults
    Expert Opinion on Pharmacotherapy ISSN: 1465-6566 (Print) 1744-7666 (Online) Journal homepage: http://www.tandfonline.com/loi/ieop20 Lifitegrast for the treatment of dry eye disease in adults Eric D. Donnenfeld, Henry D. Perry, Alanna S. Nattis & Eric D. Rosenberg To cite this article: Eric D. Donnenfeld, Henry D. Perry, Alanna S. Nattis & Eric D. Rosenberg (2017): Lifitegrast for the treatment of dry eye disease in adults, Expert Opinion on Pharmacotherapy, DOI: 10.1080/14656566.2017.1372748 To link to this article: http://dx.doi.org/10.1080/14656566.2017.1372748 Accepted author version posted online: 25 Aug 2017. Published online: 04 Sep 2017. Submit your article to this journal Article views: 11 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ieop20 Download by: [108.6.184.233] Date: 04 September 2017, At: 04:29 EXPERT OPINION ON PHARMACOTHERAPY, 2017 https://doi.org/10.1080/14656566.2017.1372748 DRUG EVALUATION Lifitegrast for the treatment of dry eye disease in adults Eric D. Donnenfelda, Henry D. Perryb, Alanna S. Nattisb and Eric D. Rosenbergc aOphthalmic Consultants of Long Island, New York University Medical Center, Garden City, NY, USA; bOphthalmic Consultants of Long Island, Nassau University Medical Center, Rockville Centre, NY, USA; cWestchester Medical Center, Valhalla, NY, USA ABSTRACT ARTICLE HISTORY Introduction: Dry eye disease (DED) is a common ocular disorder that can have a substantial burden on Received 14 June 2017 quality of life and daily activities. Lifitegrast ophthalmic solution 5.0% is the first medication approved in Accepted 24 August 2017 the US for the treatment of the signs and symptoms of DED.
    [Show full text]
  • ADD/ADHD: Strattera • Allergy/Anti-Inflammatories
    EXAMPLES OF PERMITTED MEDICATIONS - 2015 ADD/ADHD: Strattera Allergy/Anti-Inflammatories: Corticosteroids, including Decadron, Depo-Medrol, Entocort, Solu-Medrol, Prednisone, Prednisolone, and Methylprednisolone Anesthetics: Alcaine, Articadent, Bupivacaine HCI, Chloroprocaine, Citanest Plain Dental, Itch-X, Lidocaine, Marcaine, Mepivacaine HCI, Naropin, Nesacaine, Novacain, Ophthetic, Oraqix, Paracaine, Polocaine, Pontocaine Hydrochloride, PrameGel, Prax, Proparacaine HCI, Ropivacaine, Sarna Ultra, Sensorcaine, Synera, Tetracaine, Tronothane HCI, and Xylocaine Antacids: Calci-Chew, Di-Gel, Gaviscon, Gelusil, Maalox, Mintox Plus, Mylanta, Oyst-Cal 500, Rolaids, and Tums Anti-Anxiety: Alprazolam, Atarax, Ativan, Buspar, Buspirone HCI, Chlordiazepoxide HCI, Clonazepam, Chlorazepate Dipotassium, Diastat, Diazepam, Hydroxyzine, Klonopin, Librium, Lorazepam, Niravam, Tranxene T-tab, Valium, Vistaril, and Xanax Antibiotics: Acetasol HC, Amoxil, Ampicillin, Antiben, Antibiotic-Cort, Antihist, Antituss, Avelox, Ceftazidime, Ceftin, Cefuroxime Axetil, Ceptaz, Cleocin, Cloxapen, Cortane-B Aqueous, Cortic, Cresylate, Debrox, Doryx, EarSol-HC, Fortaz, Gantrisin, Mezlin, Moxifloxacin, Neotic, Otocain, Principen, Tazicef, Tazidime, Trioxin, and Zyvox Anti-Depressants: Adapin, Anafranil, Asendin, Bolvidon, Celexa, Cymbalata, Deprilept, Effexor, Elavil, Lexapro, Luvox, Norpramin, Pamelor, Paxil, Pristiq, Prozac, Savella, Surmontil, Tofranil, Vivactil, Wellbutrin, Zoloft, and Zyban Anti-Diabetics: Actos, Amaryl, Avandia, Glipizide, Glucophage,
    [Show full text]
  • 1: Gastro-Intestinal System
    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
    [Show full text]